Drug Combination Details
| General Information of the Combination (ID: C99451) | |||||
|---|---|---|---|---|---|
| Name | Verminoside NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Afer 1 week of NC13 or Vms pre-treatment, 0.5*105 of 4T1 cells were subcutaneously injected into the mammary fat pad of each mouse. | |||||
| Experimental
Result(s) |
Verminoside sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer. | |||||
